Literature DB >> 19147828

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Maria Paola Martelli1, Gabriella Sozzi, Luis Hernandez, Valentina Pettirossi, Alba Navarro, Davide Conte, Patrizia Gasparini, Federica Perrone, Piergiorgio Modena, Ugo Pastorino, Antonino Carbone, Alessandra Fabbri, Angelo Sidoni, Shigeo Nakamura, Marcello Gambacorta, Pedro Luis Fernández, Jose Ramirez, John K C Chan, Walter Franco Grigioni, Elias Campo, Stefano A Pileri, Brunangelo Falini.   

Abstract

A fusion gene, echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear. Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls. In cases carrying the fusion transcript, we determined EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunoprecipitation. We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the molecular studies. EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor. Notably, no transcripts were detected in matching tumor samples from these patients. Fluorescence in situ hybridization analysis of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene. None of these cases was found to express the EML4-ALK protein as examined by immunohistochemistry, Western blotting, and immunoprecipitation. The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147828      PMCID: PMC2630573          DOI: 10.2353/ajpath.2009.080755

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  ALK is not expressed in Hodgkin disease.

Authors:  S Camilleri-Broët; J Audouin; C Fermé; J Brière; K Pulford; P Gaulard; M Diviné; E Macintyre; G Delsol; F Berger
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.

Authors:  B Falini; K Pulford; A Pucciarini; A Carbone; C De Wolf-Peeters; J Cordell; M Fizzotti; A Santucci; P G Pelicci; S Pileri; E Campo; G Ott; G Delsol; D Y Mason
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

Review 5.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.

Authors:  Brunangelo Falini; David Y Mason
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

Authors:  K Pulford; L Lamant; S W Morris; L H Butler; K M Wood; D Stroud; G Delsol; D Y Mason
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?

Authors:  K Orscheschek; H Merz; J Hell; T Binder; H Bartels; A C Feller
Journal:  Lancet       Date:  1995-01-14       Impact factor: 79.321

10.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

View more
  111 in total

Review 1.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 2.  Targeted therapies for non-small cell lung cancer: an evolving landscape.

Authors:  Sumanta Kumar Pal; Robert A Figlin; Karen Reckamp
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

Review 3.  The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers.

Authors:  Yu Zhang; Monica Gostissa; Dominic G Hildebrand; Michael S Becker; Cristian Boboila; Roberto Chiarle; Susanna Lewis; Frederick W Alt
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

4.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Authors:  D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

5.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 6.  Mutation-associated fusion cancer genes in solid tumors.

Authors:  Frederic J Kaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

7.  Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.

Authors:  Bhasker Radaram; Federica Pisaneschi; Yi Rao; Ping Yang; David Piwnica-Worms; Mian M Alauddin
Journal:  Eur J Med Chem       Date:  2019-08-09       Impact factor: 6.514

Review 8.  Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Authors:  Thierry Berghmans; Myriam Remmelink; Ahmad Awada
Journal:  Lung Cancer (Auckl)       Date:  2012-12-17

Review 9.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

Review 10.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.